mCapOX plus cetuximab — Competitive Intelligence Brief

mCapOX plus cetuximab (mCapOX plus cetuximab) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Platinum-based chemotherapy, EGFR inhibitor. Area: Oncology.

phase 3 Platinum-based chemotherapy, EGFR inhibitor EGFR Oncology Small molecule

Target snapshot

mCapOX plus cetuximab (mCapOX plus cetuximab) — West China Hospital. mCapOX is a chemotherapy drug that works by inhibiting DNA replication, while cetuximab is a monoclonal antibody that targets the epidermal growth factor receptor (EGFR).

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
mCapOX plus cetuximab TARGET	mCapOX plus cetuximab	West China Hospital	phase 3	Platinum-based chemotherapy, EGFR inhibitor	EGFR
Rybrevant	AMIVANTAMAB	Johnson & Johnson	marketed		EGFR, MET	2021-01-01
NERATINIB	NERATINIB		marketed		EGFR, HER2, HER4	2017-01-01
Inlyta	Axitinib	Pfizer	marketed	Receptor tyrosine kinase inhibitor	Vascular endothelial growth factor receptors (VEGFR)-1, VEGFR-2, VEGFR-3	2012-01-01
REGORAFENIB	REGORAFENIB		marketed		RET, VEGFR1, VEGFR2, VEGFR3, KIT, PDGFR-alpha, PDGFR-beta, FGFR1, FGFR2, TIE2, DDR2, TrkA, Eph2A, RAF-1, BRAF, BRAF V600E, SAPK2, PTK5, Abl, CSF1R	2012-01-01
PONATINIB HYDROCHLORIDE	PONATINIB HYDROCHLORIDE		marketed		ABL, T315I mutant ABL, VEGFR, PDGFR, FGFR, EPH receptors, SRC family, KIT, RET, TIE2, FLT3	2012-01-01
PAZOPANIB	PAZOPANIB		marketed	Kinase Inhibitor [EPC]	VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-ɑ, PDGFR-β, FGFR-1, FGFR-3, Kit, Itk, Lck, c-Fms	2009-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Platinum-based chemotherapy, EGFR inhibitor class)

1. West China Hospital · 1 drug in this class